Mortality rates for ovarian cancer have declined only slightly in the past forty years since the "War on Cancer" was declared. The current standard care of ovarian cancer is still cytoredutive surgery followed by several cycles of chemotherapy. The severe adverse effect from chemotherapy drug is a leading cause for the patients to fail in long term therapy post-surgery. New nanocarriers able to minimize the premature drug release in blood circulation while releasing drug on-demand at tumor site have profound impact on the improvement of the efficacy and toxicity profile of the chemotherapeutic drugs. Here we reported a unique type of extremely long tumor retention, multi-responsive boronate crosslinked micelles (BCM) for ovarian cancer therapy. We systemically investigated the stability of BCM in serum and plasma, and their responsiveness to acidic pH and cis-diols (such as mannitol, a safe FDA approved drug for diuresis) through particle size measurement and förster resonance energy transfer (FRET) approach. Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher stability than noncrosslinked micelles (NCM) in the presence of plasma or serum. BCMs possessed a longer in vivo blood circulation time when compared to NCM. Furthermore, BCM could be disassembled in an acidic pH environment or by administrating mannitol, facilitating drug release in an acidic tumor environment and triggered by exogenous stimuli after drug enrichment in tumor mass. Near infra-red fluorescence (NIRF) imaging on SKOV-3 ovarian cancer mouse model demonstrated that the NIR dye DiD encapsulated BCM could preferentially accumulate in tumor site and their tumor retention was very long with still 66% remained on 12th day post injection. DiD-NCM had similar high-level uptake in tumor with DiD-BCM within the first 3 days, its accumulation, however, decreased obviously on 4th day and only 15% dye was left 12 days later. In both formulations, the dye uptake in normal organs was mostly washed away within the first 24-48 h. In in vivo tumor treatment study, PTX loaded BCM showed superior therapeutic efficacy than that of NCM and Taxol. The mice could tolerate 20 mg/kg PTX formulated in nano-formulations, which doubled the maximum tolerated dose (MTD) of Taxol. The administration of mannitol 24 h after BCM-PTX injection further improved the tumor therapeutic effect and elongated the survival time of the mice. The novel boronate-catechol crosslinked nanocarrier platform demonstrated its superior capability in targeted drug delivery, which is not only useful for ovarian cancer treatment but will also be beneficial for the therapy of many other solid tumors.
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Introduction
Ovarian cancer exits as the 5th malignancy resulting in death in female patients. The American Cancer Society estimated that in 2017, about 22,440 new cases of ovarian cancer would be diagnosed and 14,080 women would die of ovarian cancer in the United States [1] . Most epithelial ovarian cancers are diagnosed at an advanced stage where the tumor has seeded the abdominal cavity (stage 3) [2, 3] . The current therapeutic treatments for epithelial ovarian cancers include the use of combination chemotherapy with a platinum based drug and paclitaxel (PTX) [4] [5] [6] [7] [8] [9] . If the patient has had an optimal cytoreductive surgery (< 1 cm of residual tumor burden) then the current gold standard of treatment involves intravenous (IV) PTX on Day 3 weeks a cycle, repeated a total of 6 cycles. Many patients are unable to complete six cycles due to the debilitating side effects of the chemotherapy. For PTX, these include hypersensitivity reactions, neurotoxicity, and myelosuppression [4] [5] [6] [7] [8] [9] [10] . Optimizing drug delivery while decreasing side effects is critical to improve the therapeutic nature of these drugs while also improving a patient's quality of life [11] [12] [13] [14] [15] .
In the past 10-15 years, nanotechnology has been intensively developed to apply in the field of cancer therapy [12] [13] [14] [15] . Polymeric micelles demonstrated their superior potential in drug delivery for cancer therapy in several aspects, such as superior capability to encapsulate water insoluble chemotherapeutic drugs, prolonged in vivo circulation time and preferential accumulation at tumor site via the enhanced permeability and retention (EPR) effect due to their relatively smaller particle size (< 100 nm) [11, [16] [17] [18] [19] [20] [21] . However, there are some challenges that have hampered the clinical translation of this type of nanoparticles. Polymeric micelles typically are a thermo-dynamic system because they are formed through self-assembled procedure in certain buffer system. It is well-known that a delicate equilibrium exhibits between micelles and unimers in different buffer conditions [22, 23] . Blood is the first biological barrier for micelle-based drug delivery systems via IV administration. It has been demonstrated that the interaction with blood proteins and lipoproteins (e.g. HDL, LDL, VLDL and chylomicron) may cause the dissociation of these thermo-dynamic nanoparticles and lead to premature drug release [24] . Furthermore, conventional polymeric micelles may be dissociated into unimers after IV administration owing to their susceptibility to dilution below the critical micelle concentration (CMC) [22, 23] . This is another factor that may result in early dissociation of the micelles and premature drug release before micelles reaching and accumulating in the tumor location.
Herein, researchers have put more efforts to search for feasible ways to improve the stability of polymeric micelles for in vivo drug delivery. Cross-linking approaches have exhibited as one of an ideal choice [25, 26] . A programmable cross-linking strategy to control the release rate of the entrapped drugs in different environments (e.g. normal organs versus tumor) is ideal to minimize the systemic toxicity and enhance the therapeutic efficacy of the chemotherapeutic agents. This led to the development of stimuli-responsive cross-linked micelles (SCMs), a smart nanocarrier system for tumor-targeting drug delivery and on demand drug release [19, 23, [27] [28] [29] . SCMs possessed minimal premature drug release due to their superior structural stability in blood stream while they could be triggered to release drug payloads in response to the local environment of the tumor (e.g. tumor extra-cellular pH 6.5-7.2 and endosomal/lysosomal pH 4.5-6 [30, 31] , tumor reductive intra-cellular conditions [19, 23, 26, [32] [33] [34] [35] , adenosine triphosphate (ATP) [36] [37] [38] and enzymes [23] ) or exogenous reagents (e.g. NAcetylcysteine and cis-diols [22, 23, 39] . SCMs have shown great potential to decrease drug accumulation at normal organs to minimize the systemic toxicity and increase the therapeutic index due to their ondemand drug releasing nature at tumor sites.
Boronic acids and cis-diols can form reversible boronate esters, which is responsive dually to external pH value and competing diols [31, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . Boronate esters have been developed as building blocks in designing stimuli-responsive drug delivery systems. Due to their synperi-planar arrangement of the aromatic hydroxy groups and electrondonating character, catechols are an ideal type of diols to form stable boronate ester bond with boronic acids in physiological condition [31] . In the present manuscript, we describe the preclinical development of a unique type of extremely long tumor retention, multi-responsive boronate crosslinked micelles (BCM) for ovarian cancer therapy (Fig. 1) . We utilized förster resonance energy transfer (FRET) approach and particle size measurement to systemically investigate the stability and release profiles of BCM in blood related media such as serum and plasma, and their responsiveness to acidic pH and mannitol. The longterm in vivo biodistribution and blood elimination kinetics of BCM were evaluated in SKOV-3 ovarian cancer mouse models. The therapeutic efficacy and toxicity profiles of BCM entrapped with PTX were further evaluated. To the best of our knowledge, this is the first demonstration of a multi-responsive micelle-based drug delivery system with such long tumor retention (up to 12 days). 18 (DiO) and the red-orange dye rhodamine B were purchased from Invitrogen (Carlsbad, CA). Cholic acid and all other chemicals were purchased from Sigma Aldrich (St. Louis, MO).
Materials and method

Synthesis of telodendrimers
In order to synthesize boronate crosslinked micelles, two distinct building blocks were needed, including telodendrimers containing four 3-Carboxy-5-nitrophenylboronic acid (named as PEG 5k -NBA 4 -CA 8 ) and telodendrimers containing four 3,4-Dihydroxybenzoic acids (named as PEG 5k -Catechol 4 -CA 8 ) (Fig. S1 ) [31] . These telodendrimers were synthesized via solution-phase condensation reactions from MeO-PEG-NH 2 via stepwise peptide chemistry. The PEG 5k -CA 8 parent telodendrimer was synthesized to prepare the non-cross-linked micelles according to our previously reported method [11] . To make telodendrimers with fluorescent labeling, rhodamine B isothiocyanate was covalently attached to the amino group of the proximal lysine between PEG and cholic acids in the final telodendrimers [31] .
Preparation of DiD, DiO or PTX loaded micelles
Hydrophobic dye (DiO or DiD) and hydrophobic anti-cancer drug, such as paclitaxel (PTX) were encapsulated into the micelles by the solvent evaporation method as described in our previous studies [22, 31] . Boronate ester bonds formed between boronic acids and catechols of adjacent telodendrimers, upon self-assembly in 1× PBS (All the rest of PBS mentioned are 1× PBS), resulted in the formation of boronate cross-linked micelles (BCM) and drug or dye was encapsulated. Briefly, certain amount of drug or dye, boronic acid-containing telodendrimer and catechol-containing telodendrimer (total 20 mg) were first dissolved in anhydrous chloroform in a 10 mL round bottom flask. The chloroform was evaporated under vacuum to form a thin film. PBS buffer (1 mL) was added to re-hydrate the thin film, followed by 30 min of sonication. The unloaded PTX or dye was removed by running the micelle solutions through centrifugal filter devices (MWCO: 3.5 kDa, Microcon®). The PTX or dye loaded micelles on the filters were recovered with PBS.
The amount of drug loaded in the micelles was analyzed on a HPLC system (Waters) equipped with a diode array UV detector after releasing the drugs from the micelles by adding 9 times of acetonitrile and 10 min sonication. The mobile phase consisted of a mixture of water and acetonitrile (50:50, v/v%). C18 analytical column (150 mm 4.6 mm, 5 μm, Waters) was employed to separate the samples, and the flow speed was set to 1 mL/min. The whole eluting procedure lasted for 10 min. The calibration curve of PTX was obtained using a series of drug/DMSO standard solutions with different concentrations. The drug loading was calculated according to the calibration curve between the HPLC area values and concentrations of standard. The loading efficiency is defined as the ratio of drug loaded into micelles to the initial drug content. The amount of dye loaded in the micelles was analyzed on a fluorescence spectrometry (SpectraMax M2, Molecular Devices, USA) after releasing the drugs from the micelles by adding 9 times of acetonitrile and 10 min sonication. The dye loading was calculated according to the calibration curve between the fluorescence intensity and concentrations of dye standard in acetonitrile. The final micelle solution was filtered with 0.22 μm filter to sterilize the sample.
Characterizations of micelles
The size and size distribution of the micelles were measured by dynamic light scattering (DLS) instruments (Microtrac). The micelle concentrations were kept at 1.0 mg/mL for DLS measurements. Each sample was measured for three times with an acquisition time of 30 s at room temperature. The data were analyzed by Microtrac FLEX Software 10.5.3 and values were reported as the means for each triplicate measurements. The morphology of micelles was observed on a Philips CM-120 transmission electron microscope (TEM). The aqueous micelle solution (1.0 mg/mL) was deposited onto copper grids, stained with phosphotungstic acid, and measured at room temperature.
Stability investigations of PTX loaded micelles in SDS and human plasma
To investigate the stability of PTX loaded micelles, the change in particle size of NCM and BCM after encapsulation of PTX was monitored in the presence of sodium dodecyl sulfate (SDS), which was reported to be able to efficiently break down polymeric micelles [22, 23] . The final concentration of micelles was kept at 1.0 mg/mL while that of SDS was 2.5 mg/mL. The size and size distribution of the micelle solutions was monitored continuously via DLS instruments for 2 days. The stability of the micelles was also evaluated in PBS at different pH levels or in presence of mannitol and glucose (0, 10 mM, 50 mM, and 100 mM), together with SDS. Hydrogen chloride and sodium hydroxide solutions were used to prepare PBS at different pH levels. The pH values of the buffer were determined by a digital pH meter (Φ350 pH/Temp/ mV meter, Beckman Coulter, USA) which gave pH values within 0.01 units. During the stability study, a small portion of the samples were taken out and further observed under TEM. The stability of NCM and BCM was further studied in 50% (v/v) plasma from healthy human volunteers. The mixture was incubated at physiological body temperature (37°C) followed by size measurements at predetermined time intervals up to 96 h. Micelles with DiO alone and micelles with rhodamine B alone at the same dye contents were also prepared for comparison. The micelle solution was filtered with 0.22 μm filter to sterilize the sample. The absorbance and fluorescence spectra of these micelles diluted by PBS were characterized by fluorescence spectrometry (SpectraMax M2, Molecular Devices, USA). The excitation was set to 480 nm while the emission was recorded from 500 nm to 660 nm. The FRET ratio was calculated by the formula of (I rhodamine B / (I rhodamine B + I DiO )), where I rhodamine B and I DiO were fluorescence intensity of rhodamine B at 580 nm and DiO at 530 nm, respectively. The FRET signal changes were evaluated in PBS as well as in fetal bovine serum (FBS) at different pH levels or in presence of mannitol and glucose.
In vitro FRET studies
Animal and tumor xenograft model
Female athymic nude mice (Nu/Nu strain), 6-8 weeks age, were purchased from Harlan (Livermore, CA). All animals were kept under pathogen-free conditions according to AAALAC guidelines and were allowed to acclimatize for at least 4 days prior to any experiments. All animal experiments were performed in compliance with institutional guidelines and according to protocols approved by the Animal Use and Care Administrative Advisory Committee at the University of 
In vivo blood elimination kinetics and long-term biodistribution
To compare the pharmacokinetics of NCM and BCM, we injected 100 μL of DiD (0.5 mg/mL) loaded micelles (20 mg/mL) into nude mice bearing SKOV-3 avian cancer xenografts via tail vein. At pre-determined time points, 50 μL of blood were collected and DiD fluorescence signal in the serum were measured using fluorescence spectrometry (SpectraMax M2, Molecular Devices, USA). For long-term biodistribution study, nude mice with established subcutaneous SKOV-3 xenograft tumors (8-10 mm in diameter) were subjected to in vivo NIRF optical imaging. After injected 100 μL of DiD and PTX co-loaded BCM (0.5 mg/ mL of DiD; 0.5 mg/mL of PTX), whole mouse NIRF imaging were acquired under general anesthesia at different time points on a Kodak multimodal imaging system IS2000MM with an excitation bandpass filter at 625 nm and an emission at 700 nm. At each time point, mice were sacrificed and all major organs and tumors were harvested for acquiring ex vivo NIRF imaging.
In vivo therapeutic and toxicity studies
Anti-cancer efficacy study was performed on SKOV-3 xenograft mouse model. Briefly, after the tumors reached a volume of 100-200 mm , and body weight were monitored twice a week and mice were monitored daily for its appearance, hair coat, behavior, and spirits. Of note, 10 mg/kg Taxol was chosen as it was close to its maximum tolerated dose (MTD) [11, 49] . We previously showed that the MTD for NCM-PTX formulation could reach 75 mg/kg [11] . Therefore, we included the 20 mg/kg as a higher dose level for both BCM-PTX and NCM-PTX groups to evaluate if the anti-cancer efficacy could be further improved. Mannitol solutions were IV administered 24 h post-injection and were used to trigger drug release from BCM-PTX in tumor site. When tumor size reached 1500 mm 3 , for humane reasons, animals were terminated. Animal survival data were recorded till day 82. To monitor potential toxicity, the body weight of each mouse was measured every 3 days. At day 6 after the last dose, blood samples were collected from each group to test blood cell counts and serum chemistry.
Statistical analysis
Statistical analysis was performed by Student's t-test for two groups, and oneway ANOVA for multiple groups. All results were expressed as the mean ± standard error (mean ± SEM) unless otherwise noted. A value of P < 0.05 was considered statistically significant.
Results and discussion
Characterizations of PTX-loaded BCMs
BCM were formed by the self-assembly of two distinct telodendrimers: boronic acid-containing telodendrimer (PEG 5k -NBA 4 -CA 8 ) and catechol-containing telodendrimers (PEG 5k -Catechol 4 -CA 8 ) (Fig. S1 ).
Upon the self-assembly of PEG 5k -NBA 4 -CA 8 and PEG 5k -Catechol 4 -CA 8 in PBS, in situ crosslinkages were formed by boronate ester bonds between boronic acids and catechols of adjacent telodendrimers, resulting in the formation of boronate cross-linked micelles (BCM) (Fig. 1) [31] . Nitrophenylboronic acid was chosen over phenylboronic acid because pKa of nitro-phenylboronic acid is lower (6.9) [31, 48] and therefore the resulting crosslinkage is expected to be more stable at physiological pH of the blood. A wide-spectrum anti-tumor agent, PTX, could be successfully encapsulated into the hydrophobic interior of BCMs simultaneously. At an initial PTX level at 2.0 mg/mL, the drug loading was almost 2.0 mg/mL while the entrapment efficiencies were 100 ± 5%. The final particle sizes of PTX-loaded BCMs (BCM-PTX) were in the range of 20-30 nm as observed under TEM (Fig. 2) . The morphology of these PTX loaded BCMs was observed to be spherical (Fig. 2) . The size of the micelles observed under TEM were consistent with those measured by DLS (Fig. 3D ).
The particle size of PTX-BCMs under different conditions
The intra-micellar boronate ester crosslinkages of BCM-PTX greatly enhanced their stability in physiological conditions in human plasma as well as severe micelle-disrupting conditions with neutral pH. DLS instrument was used to measure the size and size distribution of BCM-PTX, from which the stability of micelles could be evaluated. The stability of PTX loaded non-crosslinked micelles (NCM-PTX) and BCM-PTX were investigated in the presence of plasma, SDS, adjusted pH and mannitol. The average particle size of NCM-PTX increased in the presence of plasma and the size distribution became much broader, indicating the formation of big aggregations upon interaction with blood proteins (Table 1 , Fig. 3A and B) . In contrast, the size of BCM-PTX with the presence of plasma was almost the same with that in the absence of plasma ( Fig. 3D and E) . The NCM-PTX disassembled shortly after treated with SDS (Fig. 3C) . However, BCM-PTX still kept intact in SDS (Fig. 3F ) with pH 7.4, only dissociating when pH was adjusted to 5.0 (Fig. 3G ) or when mannitol (Fig. 3H) was supplemented in the solution. The addition of glucose did not show similar effect as that of mannitol (Fig. 3I) . Collectively, the BCM-PTX was stable in normal plasma, in glucose solution and in physiologic pH with the presence of strong micelle-disrupting agents SDS, which implied that the nanomicelle was able to keep integrity in normal blood system, therefore could circulate for longer time. In addition, the BCM-PTX could be dissociated when they were treated with acidic condition or mannitol, which meant that the loaded PTX could be released in a controllable manner. Mannitol is a safe FDA approved drug for diuresis. A high blood level of mannitol (> 50 mM) can be achieved clinically based on the recommended dose. Mannitol can thus be applied in vivo as an on-demand cleavage reagent by systemic IV injection to trigger drug release after the drug-loaded BCM have accumulated in tumor sites. The above results generally indicated that BCM-PTX possessed superior stability in the presence of plasma compared to NCM-PTX. Furthermore, BCM-PTX could 
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disassemble in an acidic environment (intratumor or lysosome) or in the presence of mannitol, which is an important feature for the intratumor or on-demand drug release.
pH-and sugar-response of boronate crosslinked micelles detected by FRET
FRET is a physical phenomenon first described over 50 years ago. FRET relies on the distance-dependent transfer of energy from a donor molecule to an acceptor molecule. FRET is a powerful technique to probe the molecular proximity of a fluorescent donor-acceptor pair and has been widely applied in the investigation of a variety of biological molecular interaction [50, 51] . Recently, FRET technique has been utilized to probe the stability and drug release profile of micelles [24, 52, 53] . In this paper, we developed a FRET system to further evaluate the stability and drug release of our boronate-crosslinked micelles in serum and/or in the presence of acidic pH and mannitol. We constructed the FRET pair with a green dye DiO (donor) and a redorange dye rhodamine B (acceptor) (Fig. 4, Figs. S2, S3) . DiO was encapsulated in the core of micelles as the hydrophobic drug surrogate to track the payloads. Rhodamine B was covalently conjugated to the telodendrimers to track the nanocarriers. Both FRET-NCM [24] and FRET-BCM were very stable in PBS at pH 7.4, thus there was little change in FRET signal over time (Fig. S3) . However, a dramatic decrease in FRET signal for FRET-NCM was observed within 30 min in the presence of fetal bovine serum (FBS) (Fig. 4A) , probably due to the interaction of micelles with blood proteins and lipoprotein nanoparticles (e.g. LDL, HDL, VLDL) in FBS. The FRET ratio decreased to Fig. 3 . The particle size of paclitaxel loaded non-crosslinked micelles (NCM-PTX) in the absence (A) and in the presence (B) of plasma 50% (v/v) for 24 h; The particle size of NCM-PTX in the presence of 2.5 mg/mL SDS for 10 s (C);The particle size of boronate crosslinked micelles (BCM-PTX) in the absence (D) and in the presence of plasma 50% (v/v) for 24 h (E);The particle size of BCM-PTX in the presence of 2.5 mg/mL SDS for 120 min (F);The particle size of BCM-PTX in SDS for 120 min and then adjusted the pH of the solution to 5.0 for 20 min (G); The particle size of BCM-PTX in SDS for 120 min and then treated with mannitol (100 mM) for 20 min (H); The particle size of BCM-PTX in SDS for 120 min and then treated with glucose (100 mM) for 20 min. The particle size was measured by DLS (Microtrac).The concentration of micelles was kept at 1.0 mg/mL in PBS.
A. NCM-PTX D. BCM-PTX G. BCM-PTX+SDS (pH 5.0) B. NCM-PTX+plasma
Table 1
The particle size of paclitaxel loaded non-crosslinked micelles (NCM-PTX) and boronate crosslinked micelles (BCM-PTX) under various conditions. In vivo blood elimination of DiD-loaded BCM and NCM in nude mice bearing SKOV-3 ovarian cancer xenograft (DiD: 0.5 mg/mL, 100 μL injection volume) (n = 3).
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29% at 6 h ( Fig. 5 cyan line) . On the contrary, there was much less change in the FRET signal for FRET-BCM up to 24 h in the present of FBS (Figs. 4B, 5 , black line). The boronate crosslinking significantly increased the stability of micelles, preventing the interactions of micelles with blood proteins in FBS, therefore minimizing the drop of FRET signal. The response of BCM to pH and mannitol was studied by detecting the change in FRET signal over time in FBS. There was a significant decrease of FRET signal when mannitol and acidic pH 5.0 were present respectively (Fig. S4A & B, Fig. 5 red line & green line) compared to that in FBS only (Figs. 4B, 5, black line) . The most dramatic decrease of FRET signal of BCM could be observed when mannitol and acidic pH 5.0 were present concurrently (Figs. 5 blue line, 6 ). The rapid decrease from 89% to 38% in FRET signal was observed within the initial 1.5 h (Fig. 5 blue line) . As a control, high concentration of glucose (100 mM) only had minimal affect on the FRET signal of BCMs (Fig. 5  purple line) . The results from FRET studies further demonstrated that BCM possessed significantly enhanced in vitro stability and was ready to disintegrate and release the payload in the presence of acidic pH and/or mannitol, which was in agreement with the results from the size measurement under various conditions.
In vivo blood elimination kinetics
To explore and compare the effects of boronate ester crosslinked nanoparticles on drug elimination in blood stream of live animals, we loaded a hydrophobic NIRF dye, DiD, into BCM serving as a drug surrogate. We compared the in vivo blood elimination kinetics DiD loaded BCM with DiD loaded NCM. As shown in Fig. S5 A & B, we first confirmed that the loading level of DiD was equivalent in BCM and NCM based on the absorbance and fluorescence analysis. DiD loaded BCM and NCM were injected via tail vein into nude mice bearing SKOV-3 ovarian cancer, blood was collected at different time points up to 32 h (Fig. 7) . The serum fluorescence intensity peaked at 1.5 and 4 h postinjections of NCM and BCM, respectively. In contrast to NCM formulation, fluorescence from BCM formulation was still detectable even at 32 h after injection. Most importantly, BCM exhibited significantly greater area under curve (AUC) compared to NCM (Fig. 7) . Consistent with previous in vitro stability studies, these results strongly support the conclusion that BCM exhibited better in vivo stability than NCM. It should be noted that the peak values in the curve of BCM and NCM were reached at 4 h and 1.5 h after injection, respectively, but not at the very beginning. By comparing the fluorescence intensity in PBS and DMSO, we observed fluorescence quenching in both DID loaded NCM and BCM (Fig. S5B) . With gradual dissociation of the nanoparticles, more and more DiD dye without signal quenched was released into blood stream to induce a lagged peak.
Prolonged retention of DiD-loaded BCM in ovarian cancer xenografts
To evaluate and compare the tumor targeting efficiency of BCM and NCM, DiD and PTX co-loaded BCM and NCM were administrated into nude mice bearing SKOV-3 ovarian cancer xenograft intravenously and the in vivo and ex vivo optical imaging were performed at pre-determined time points up to 12 days post-injection. Both DiD-PTX BCM and DiD-PTX NCM showed obvious tumor accumulation and reached peaks at around 24 h post-injection (Fig. 8A & B) , but their accumulation decreased at different rate (Figs. 8 & 9) . The uptake of both nanoformulations in tumor maintained at a high level within first 3 days. The uptake plateau for DiD-PTX BCM lasted to 7th day while the accumulation for DiD-PTX NCM showed obvious decrease starting from the 4th day. On 12th day after injection, there was 66% of DiD-PTX-BCM still kept in tumor but only 15% remained for DiD-PTX NCM (Fig. 9) . In general, both BCM and NCM were able to deliver DiD and PTX into tumor, but BCM showed longer tumor retention. It was noted that in both nano-formulations there were moderate degrees of liver, lung and interstine accumulation of DiD fluorescence signal in the early time-points, but that non-specific accumulation degraded quickly (eliminated from the body) while tumors remained with high amount of NIRF signals (Fig. 9) . The off-target uptake in normal organs such as liver or lung is a common phenomenon for nanoparticles. Our group had reported that slightly negative charge could be introduced to the nanoparticles surface to reduce the undesirable clearance by the reticuloendothelial system (RES) such as liver [54] , which was one of ways beneficial to reducing nonspecific uptake in normal organs.
Collectively, these results demonstrated that, compared with NCM, BCM was able to more specifically and efficiently deliver their payload to ovarian cancer xenograft and remain at a higher concentration in the tumor for a long time (at least 12 days). This result has great therapeutic implication as it illustrated that payload inside the boronate crosslinked nanoparticles could retain in the tumor site for multiple days, thus allowing sustained in situ therapy to the tumor while sparing normal organs. This tumor selective and long-term retention effect allows sustained anti-cancer effects and decreased toxicity toward normal organs.
Therapeutic efficacies of PTX-loaded BCM
The standard treatment for ovarian cancer was mentioned above. After optimal tumor debulking, PTX (IV) at day 1, Cisplatin (IP) at day 2 and PTX (IP) at day 8 are sequentially applied every 3 weeks for total 6 cycles. A big issue for the chemotherapy is the patients could not tolerate the severe side effects such as hypersensitivity reactions, neurotoxicity, and myelosuppression etc. [10, [55] [56] [57] . Here we investigated that whether BCM with encapsulated chemotherapeutic agents could facilitate improved drug delivery to the tumor environment for enhanced therapeutic efficacy, and reduced the systemic toxicity. We evaluated the therapeutic efficacy of BCM-PTX on nude mice bearing SKOV-3 tumor xenograft with the groups and treatments indicated in Fig. 10 . Mice were treated twice a week with a total dose of 7. It was important to note that SKOV-3 tumor xenograft in this experiment appeared to be resistant to the Taxol therapy. Nevertheless, both BCM-PTX and NCM-PTX exhibited significantly superior anti-cancer efficacy and prolonged survival compared to free Taxol at 10 mg/kg (p < 0.05) ( Fig. 10 A & B) . Specifically, the medium survival times for 10 mg/kg Taxol, NCM-PTX and BCM-PTX were 27.5, 34, and 43 days, respectively. The therapeutic efficacy was improved even further when mice were treated with mannitol at 24 h after the injection of BCM-PTX for triggering the drug release on-demand when these nanoparticle drugs accumulated at the tumor sites ( Fig. 10 A & B) . This treatment could significantly prolong the medium survival days to 51.5 days. In this study, we also treated animals with both PTX nano-formulations (NCM-PTX and BCM-PTX) at 20 mg/kg (double the MTD dose of Taxol) to see if we could further enhance anti-cancer efficacy. We found that all mice were able to tolerate this dose level (20 mg/kg) without obvious body weight loss. At this high dose (20 mg/kg), all tumors shrank 50-70% (NCM-PTX: 54%, DCM-PTX: 70%, DCM-PTX plus mannitol: 74%) and some of them even achieved complete remission. Although some tumors appeared to regrow after day 50, BCM-PTX was significantly more efficacious than NCM-PTX at 20 mg/kg, while BCM-PTX with mannitol further advanced the anti-cancer efficacy (Fig. 10 A & B) . The medium survival time for 20 mg/kg NCM-PTX, BCM-PTX, and BCM-PTX plus mannitol were 72, 81, and > 82 days, respectively. The complete tumor response rate of 33% was achieved with the combination treatment of BCM-PTX and mannitol. In contrast, the complete tumor response rate is only 10% for the same treatment group without manntiol.
Systemic toxicity was first monitored based on the body weight change and no significant body weight loss was noted in all groups. We further collected blood 6 days post last treatment and analyzed complete blood count (CBC) and serum chemistry for liver/kidney functions. As shown in Tables S1 and S2, no obvious toxicity was noted and all values were within the normal range. These results suggested that even with the administration of BCM-PTX at the level equivalent to twice of the MTD doses of free drug, mice could still tolerate and no significantly increased toxicity was observed.
Collectively, BCM-PTX exhibited superior therapeutic efficacy likely attributed to the prolonged drug circulation time and extremely long retention at the tumor site. The administration of mannitol with BCM-PTX could further trigger the drug release at the tumor sites and thus further enhanced the therapeutic index. Similar to NCM formulation, BCM could be given at least two folds of the MTD dose of Taxol without increased toxicity. In the other words, mice or patients could receive higher doses of chemotherapy with our novel formulation and achieve remarkable outcome without suffering from additional toxicity. It is expected that decoration of cancer cell-specific ligands on the surface of BCM would offer better delivery of even higher drug dose into tumor to achieve further enhanced therapeutic efficacy [18] . It is necessary to note that, compared with BCM, NCM did show less stability and shorter circulation time. But from the in vivo biodistribution and therapeutic experiments, NCM also demonstrated its potential to deliver DiD and PTX to tumor location, attributed to the common EPR effect of nanoparticles. Our groups had reported that drug loaded NCM was efficacious in several tumor models as well [11, 20] . Therefore, it is not surprising that PTX-NCM indicated obvious in vivo therapeutic effect in this research. PTX-BCM demonstrated its significantly improved therapeutic effect as a result of enhanced stability in 10 mg/ kg and 20 mg/kg groups. But the improved effect in group 20 mg/kg was not as great as in that of 10 mg/kg. This is likely caused by that the 7 doses of drug were administrated within first three weeks, and by the time of 6 or 7 weeks after last dose, most the drug might be washed away. An alternative way to amply the difference is to increase the number of dosing or give the supplementary dose after 6-7 weeks, which would be tested in our future experiments.
Conclusion
To improve the efficacy of chemotherapy against ovarian cancer and reduce systemic side effect from the drug, we developed an unique catechol-boronate crosslinked micellar drug delivery system. BCM demonstrated superior in vitro stability in the presence of plasma under physiological pH, but dissociated when treated with acidic pH and/or mannitol, but not with glucose. BCM also showed higher in vivo stability compared with their non-crosslinked counterpart. BCM possessed extremely long tumor retention time up to 12 days after injection in mice. After loading with PTX, BCM were demonstrated to have better therapeutic effect against SKOV-3 ovarian cancer in mouse model in contrast to that of NCM and Taxol. Furthermore, the therapeutic efficacy of BCM-PTX could be further enhanced by the administration of mannitol for triggering drug release at the tumor site on-demand. This triggering release mechanism can also be expanded to other stimuli-responsive drug delivery systems. This important observation has great translational potential and can be easily tested in clinical trials in the future as mannitol is already used in clinic at high dose. The extremely long tumor retention, multi-responsive crosslinked nano-platform shows great promise to improve the efficacy and minimize the side effect of the treatment for ovarian cancer. It could be potentially utilized to treat many other tumor types beside ovarian cancer after loading with corresponding chemotherapy drugs.
